REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Regenxbio (RGNX) Misses Q2 EPS by 24c
August 9, 2021 4:48 PM EDTRegenxbio (NASDAQ: RGNX) reported Q2 EPS of ($1.36), $0.24 worse than the analyst estimate of ($1.12). Revenue for the quarter came in at $22 million versus the consensus estimate of $29.02 million.
Financial Guidance:
Based on its current operating plan, REGENXBIO expects its balance in... More
